- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1534-6269
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
First-Line Management of Advanced High-Grade Serous Ovarian Cancer ; volume:22 ; number:6 ; day:4 ; month:6 ; year:2020 ; pages:1-14 ; date:6.2020
Current oncology reports ; 22, Heft 6 (4.6.2020), 1-14, 6.2020
- Urheber
-
Mahmood, Reem D.
Morgan, Robert D.
Edmondson, Richard J.
Clamp, Andrew R.
Jayson, Gordon C.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11912-020-00933-8
- URN
-
urn:nbn:de:101:1-2020081123032474838478
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mahmood, Reem D.
- Morgan, Robert D.
- Edmondson, Richard J.
- Clamp, Andrew R.
- Jayson, Gordon C.
- SpringerLink (Online service)
Ähnliche Objekte (12)
High-grade serous ovarian cancer: the clone wars
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer
Principles of dormancy evident in high-grade serous ovarian cancer
MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma
No evidence for PALB2 methylation in high-grade serous ovarian cancer
Biological and prognostic value of ETV5 in high-grade serous ovarian cancer
Comparative analysis of syngeneic mouse models of high-grade serous ovarian cancer
Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma
High-throughput approaches for precision medicine in high-grade serous ovarian cancer
Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancer
Immune cell landscapes are associated with high-grade serous ovarian cancer survival
High-grade serous ovarian cancer: the clone wars
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer
Principles of dormancy evident in high-grade serous ovarian cancer
MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma
No evidence for PALB2 methylation in high-grade serous ovarian cancer
Biological and prognostic value of ETV5 in high-grade serous ovarian cancer
Comparative analysis of syngeneic mouse models of high-grade serous ovarian cancer
Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma
High-throughput approaches for precision medicine in high-grade serous ovarian cancer
Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancer
Immune cell landscapes are associated with high-grade serous ovarian cancer survival
High-grade serous ovarian cancer: the clone wars
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer
Principles of dormancy evident in high-grade serous ovarian cancer
MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma
No evidence for PALB2 methylation in high-grade serous ovarian cancer
Biological and prognostic value of ETV5 in high-grade serous ovarian cancer
Comparative analysis of syngeneic mouse models of high-grade serous ovarian cancer
Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma
High-throughput approaches for precision medicine in high-grade serous ovarian cancer
Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancer